A detailed history of Vident Advisory, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Vident Advisory, LLC holds 11,551 shares of IONS stock, worth $826,474. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,551
Previous 12,000 3.74%
Holding current value
$826,474
Previous $474 Million 59.38%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$39.94 - $65.42 $17,933 - $29,373
-449 Reduced 3.74%
11,551 $756 Million
Q2 2025

Aug 14, 2025

BUY
$25.51 - $40.0 $306,120 - $480,000
12,000 New
12,000 $474 Million
Q1 2024

May 14, 2024

SELL
$42.03 - $53.55 $5,632 - $7,175
-134 Reduced 2.72%
4,796 $208 Million
Q4 2023

Feb 14, 2024

SELL
$43.39 - $51.63 $28,463 - $33,869
-656 Reduced 11.74%
4,930 $249 Million
Q3 2023

Feb 21, 2024

BUY
$38.5 - $47.13 $25,256 - $30,917
656 Added 13.31%
5,586 $253 Million
Q3 2023

Nov 14, 2023

BUY
$38.5 - $47.13 $215,061 - $263,268
5,586 New
5,586 $253 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $10.2B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.